DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 188 filers reported holding DENALI THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 2.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $939,000 | -12.2% | 30,588 | -15.8% | 0.14% | +51.1% |
| Q2 2022 | $1,070,000 | +86.4% | 36,341 | +103.6% | 0.09% | +91.8% |
| Q1 2022 | $574,000 | -25.2% | 17,850 | +17.4% | 0.05% | -10.9% |
| Q3 2021 | $767,000 | +106.7% | 15,200 | +221.1% | 0.06% | +120.0% |
| Q2 2021 | $371,000 | -70.8% | 4,734 | -78.7% | 0.02% | -72.5% |
| Q1 2021 | $1,271,000 | -14.4% | 22,265 | +25.7% | 0.09% | -9.0% |
| Q4 2020 | $1,484,000 | -42.4% | 17,713 | -75.4% | 0.10% | -41.2% |
| Q3 2020 | $2,578,000 | +82.6% | 71,937 | +23.2% | 0.17% | +77.1% |
| Q2 2020 | $1,412,000 | +5.1% | 58,400 | -23.9% | 0.10% | -9.4% |
| Q1 2020 | $1,343,000 | +103.5% | 76,700 | +102.4% | 0.11% | +158.5% |
| Q4 2019 | $660,000 | +9.6% | 37,903 | -3.6% | 0.04% | +13.9% |
| Q3 2019 | $602,000 | +158.4% | 39,312 | +250.4% | 0.04% | +157.1% |
| Q2 2019 | $233,000 | – | 11,220 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |